Electro-Optical Sciences, Inc. (the "Company") (NASDAQ: MELA), announced today that it will be doing business under the name "MELA Sciences" to better reflect the Company's focus on early melanoma detection. The Company's shares will continue to be traded on the NASDAQ capital market under the ticker symbol "MELA."
BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, today announced the global launch of the iLase(TM) diode laser, the world's first personal laser for dentists and hygienists designed to perform a full-range of minimally invasive soft-tissue and hygiene procedures. The iLase is being introduced today at the Chicago Dental Society Midwinter Show at McCormick Place West in Chicago.
Researchers from the Ohio State University have developed a rapid, multiplexed genotyping method to identify the single nucleotide polymorphisms (SNPs) that affect warfarin dose. The related report by Yang et al, "Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry," appears in the March 2010 issue of the Journal of Molecular Diagnostics.
Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
Qioptiq, a global company which designs and manufactures photonic products and solutions, today announced that it has introduced a new and innovative intraoral camera with autofocus for the dental market.
Olympus, a precision technology leader designing and delivering innovative solutions in Medical and Surgical products among other core business areas, today introduced a 9.9-millimeter gastroscope that delivers HDTV image quality and Narrow Band Imaging (NBI). The new scope, the GIF-H180J model, is intended for upper gastrointestinal screening, diagnostic and therapeutic procedures. Its notable new feature, an auxiliary water channel, flushes away blood, mucus and other debris inside the upper gastrointestinal tract, helping to ensure a clear view at all times. Combined with the optional OFP Flushing pump, the GIF-H180J allows for faster, more convenient irrigation of the visual field.
Fujitsu Frontech North America Inc., a leading supplier of innovative computer products including peripherals and biometric security solutions, today announced that Holy Name Hospital in Teaneck, N.J. is the first hospital in New Jersey to implement the Fujitsu PalmSecure™ palm vein authentication technology for patient registration and identification. The Fujitsu PalmSecure biometric solution integrates into Holy Name's new Palm First registration system to bolster security of medical records and enhance the overall patient experience. The PalmSecure technology helps Holy Name prevent medical identify theft and comply with the Healthcare Insurance Portability and Accountability Act (HIPAA) while ensuring that patients receive care more efficiently. Fujitsu (booth #5232) will demonstrate the PalmSecure authentication solution during HIMSS10 Annual Conference & Exhibition, March 1-3, 2010 at the Georgia World Congress Center in Atlanta.
InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company will be exhibiting at LUMEN 2010, the world's premier ST-elevation myocardial infarction (STEMI) meeting, to be held February 25-27, 2010 at the Loews Miami Beach Hotel in Miami Beach, Florida. The 9th Annual LUMEN meeting is an educational symposium providing updates from world-renowned experts in key areas of interventional cardiology and vascular intervention. InfraReDx will be displaying its novel LipiScan™ Coronary Imaging System at booth #306 throughout the LUMEN meeting. InfraReDx will be available to discuss with attending clinical and interventional cardiologists, cardiac and vascular surgeons and other cardiovascular professionals LipiScan's abilities in identifying and characterizing lipid core (fatty) plaques and the importance of this novel technology.
inVisionCam™ to be demonstrated at ADEA Annual Session & Exhibition, March 1-2
Of the 200,000 men newly diagnosed with prostate cancer each year in the United States, about one-third will undergo surgical treatment. Although open radical prostatectomy (ORP) is regarded as the standard treatment, laparoscopic radical prostatectomy (LRP) with or without robotic assistance is becoming more common.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.